Advanced Filters
noise

Lupus Nephritis Clinical Trials

A listing of Lupus Nephritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 68 clinical trials
B Bogdan Obrisca, MD, PhD

Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis

The aim of the study is to evaluate the efficacy of a therapeutic regimen which decreases glucocorticoid exposure compared with standard therapy in patients with proliferative lupus nephritis during remission induction by evaluating the histological and clinical remission.

18 - 80 years of age All Phase 4
D Desmond Yap, MD

SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). Although the standard-of-care treatments for active severe LN are effective, a substantial proportion of LN patients still develop CKD and eventually end-stage …

18 years of age All Phase 2
H Hui Luo

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

18 - 70 years of age All Phase 1/2
I Ioannis Parodis, MD PhD | Associate Professor

Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis

Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Among people living with SLE, 35-60% will develop LN during the course of the disease. This complication is one of the factors that contribute to deterioration of the renal function. Some centres perform kidney biopsies …

18 years of age All Phase N/A
H He Huang, Doctor

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.

18 years of age All Phase 0

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis

This trial aims to find out if obe-cel gets rid of harmful B cells that contribute to systemic lupus erythematosus (SLE)/lupus nephritis (LN) when available treatments have not worked (refractory). The trial includes only 1 group of patients (single arm), including adolescent and adult patients aged 12 to 65 years. …

12 - 65 years of age All Phase 2
X Xia Gao, M.D.

Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children

The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory/recurrent lupus nephritis. The persistence and cell phenotype of CAR-T cells in vivo and CAR-T treatment-related inflammatory factors were evaluated after treatment. To explore new …

6 - 18 years of age All Phase 3
X Xinping Tian, MD

Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis

This is an observational study of patients with lupus nephritis aiming to find biomarkers that can predict patients' response to immunosuppressants. We planed to collect 100 lupus nephritis patients' peripheral blood,kidney tissues and urine before and after treatment (mycophenolate mofetil or cyclophosphamide, in combination with glucocorticoids). Then multi omics analysis, …

16 - 60 years of age All Phase N/A
H Huijuan Mao

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis

This is an open-label investigator-initiated trial (IIT) to assess the safety, efficacy, and PK(pharmacokinetic)/PD(pharmacodynamics ) of UB-VV410 in adult subjects with clinically active treatment-refractory SLE. The study population will include subjects with active LN (as defined by evidence of active inflammation on renal biopsy, referred to as the LN cohort) …

18 - 65 years of age All Phase 1
Y Yu Xueqing, Prof

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK010 or NK042 in combination with rituximab (RTX) for the treatment of patients with refractory systemic lupus erythematosus (SLE) or lupus nephritis (LN) in China.

18 - 65 years of age All Phase 1

Simplify language using AI